MENU

Preclinical evaluation of novel OT-analogs for the potential treatment of social behavioral deficits

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Assistant Professor, Department of Pharmacology, Midwestern University
    Biography

      Dr. Marsha Pierce is an assistant professor at Midwestern University where she studies the role of oxytocin analogs in cellular signaling and neuronal morphology and marine natural products in neuroscience drug development. Dr. Pierce received her BS in biology and MS and PhD in biomedical sciences at Creighton University. Her postdoctoral research examined the role of natural variation in oxytocin and vasopressin ligands and receptors on pharmacological signaling profiles under the mentorship of Thomas Murray at Creighton University.


    Abstract

    As pharmaceutical companies have reduced or eliminated neuroscience drug development due to high costs and low approval rates, the economic and healthcare burden of CNS disorders in the United States costs an estimated $800 billion per year and rising. In the central nervous system, arginine vasopressin (AVP) and oxytocin (OT) are expressed in the social behavioral network (SBN), which includes connections important for parental bonding, peer relationships, social perception, cognition, and decision making. Within the SBN, AVP and OT are expressed in distinct cell populations and are associated with opposing roles in behavioral and physiological functions, with AVP exerting anxiogenic and depressive-like effects and OT exerting anxiolytic and anti-depressive effects. The mammalian OT-AVP receptor family is comprised of four G-protein coupled receptors: one canonical OT receptor (OTR) and three AVP receptors (V1a, V1b, and V2). Both OTR and V1aR are robustly expressed in the brain, and share ~85% structural homology, resulting in significant cross-reactivity between their ligands. Perturbations in the OT-VP system are associated with multiple psychopathologies, thus OT has received considerable interest as a therapeutic target. Currently, OT therapeutic applications are limited due to a relatively short efficacy, poor oral bioavailability, and poor blood-brain barrier penetrance. To address this, two OT variants (Pro8-OT and Val3-Pro8-OT) with a longer half-life are being compared to effects of the endogenous OT analog (Leu8-OT). This project evaluates the effects of OT analog-induced G-protein mediated signaling and effects on neuronal structure in human derived neuronal-like SH-SY5Y cells and murine primary hippocampal culture. Collectively, these data will provide key findings into how OT affects neuronal structure and function, so that these effects can better inform OT-mediated therapeutic development in humans.

    Learning Objectives:

    1. Describe the drug development process and timeline

    2. Identify the challenges associated with neuropharmacological drug development

    3. Differentiate between agonists, partial agonists and antagonists

    4. Discuss how drug effects on cellular signaling and neuronal morphology may relate to physiological and sociobehavioral changes at the organismal level


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources
    Attendees
    • See more